Product Images Trazimera

This appears to be a graph or chart titled "Cumulative Incidence" showing the number of cases per year (or time period) on the vertical axis and the time from the initiation of Pacitaxel-frastuzumab treatment in years on the horizontal axis. Additionally, there are numbers at Rk and two labels "ACSTuH" and "ACT". However, it is difficult to interpret the meaning of the graph without additional context.*

This appears to be a graph. The title of the graph is "Cumulative incidence" and the x-axis represents "time from randomization (months)". The y-axis shows numbers from 0 to 50, with numbers at risk ranging from 0 to 1708. There are two plots on the graph, one for "observational only" and the other for "trastuzumab 1-year".*

The text contains information about medical treatment trials indicated by ACST and ACSTMH. There are also survival rates given in years and numbers at risk for each trial. Water, hydrogen peroxide, hydrogen, and oxygen also appear. This information is most likely incomplete or incorrect as most of the text is unreadable.*

Trazimera is a medication for injection administered by intravenous infusion. It contains trastuzumab-qyyp and is intended for the treatment of Cor and reland. The medication is stored in a refrigerated environment and can be used for up to 28 days after reconstitution. The medication should not be frozen and must not be shaken after reconstitution. The prescription information for preparation instructions, dosage, and administration should be consulted for further guidance. The given NDC code is 0060-0306-01.*

This is a description of a pharmaceutical product, Bacteriostatic Water for Injection, manufactured by Izor Ireland Pharmaceuticals located in Cork, Ireland. The product has a US license number 2060 and is distributed by Pfizer Labs, a division of Pfizer Inc, based in New York City. It is not intended for use in newborns and is only for diluting drugs. The product comes in a 20 ml vial and contains 1.1% benzyl alcohol and water for injection. The solution is sterile and nonpyrogenic and should be stored at a controlled room temperature between 2°C and 30°C. Full prescribing information is enclosed and the solution should only be used if the seal is intact and the solution is clear.*

This is pharmaceutical information on Trazimera, a medication used for IV administration. The text includes instructions for reconstitution, dosage, and administration of the drug. There are also details on storage, discard instructions, and contents of the multiple-dose vial. The medication should be refrigerated after reconstitution and discarded if unused after two days. It is manufactured by Pfizer and contains trastuzumab-ayyp.*

Trazimera is a pharmaceutical injection approved for use in the US. It is used via ravenous infusion after reconstitution. The lot number, expiration date, and NDC are provided. The prescribing information should be consulted for instructions on reconstitution, dilution, and dosage. Trazimera should be stored in a refrigerator in its original packaging. The unopened vial may be stored up to 30°C for up to three months but should be discarded after the expiration date. Unused reconstituted solution should also be discarded within 24 hours.*

This is a product description for Trazimera, a medication that contains 150 mg of trastuzumab. The medication is stored in single-dose vials and is intended for intravenous infusion after reconstitution. It should not be shaken after reconstitution and can be stored at temperatures up to 2°C. The lot number, expiration date, and serial number information is printed on the packaging. The medication must be diluted with 9% Sodium Chloride injection, USP before use. This medication is manufactured in Belgium and distributed by Pfizer Oncology.*